Concord Biotech USFDA ANDA nod lifts stock 10% June 3

Why Concord Biotech is in focus on June 3

Concord Biotech shares are expected to remain in focus on June 3 after the company announced a key US regulatory clearance. The company said it has received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA). The approval is for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. The update matters because the US is the largest pharmaceutical market and approvals can expand the addressable customer base. The development also comes after a sharp move in the stock price in the prior session. Investors are also weighing the news against recent performance commentary and brokerage views.

What the USFDA approval covers

The approved product is Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. Mycophenolate mofetil is described as an antimetabolite immunosuppressant. It is indicated for the prophylaxis of organ rejection in adult and pediatric recipients who are 3 months of age and older. The use cases mentioned include allogeneic kidney, heart, or liver transplants. The drug is used in combination with other immunosuppressants. Concord Biotech communicated the approval through a stock exchange intimation.

Why this product matters in transplant care

Immunosuppressants are a critical part of post-transplant treatment because they help prevent the body from rejecting a transplanted organ. The company’s announcement highlights that the therapy is relevant across kidney, heart, and liver transplant settings. The pediatric inclusion, starting from 3 months of age, broadens the eligible patient pool compared with adult-only indications. Because the drug is used alongside other immunosuppressants, demand is linked to transplant protocols rather than a single therapy decision. The approval can support portfolio depth in regulated markets. One of the notes in the provided information also pegs the US market size for this product opportunity at about US$10 million.

Stock move and key price levels investors tracked

In the previous trading session, Concord Biotech shares closed at Rs 1,166.80, up Rs 106.20 or 10.01%. Separate market data in the provided text also shows the stock at ₹1,166.2 as of 2 Jun, 2026, with an intraday range between ₹1,036.20 and ₹1,183.30. The stock’s 52-week levels were highlighted as a high of Rs 2,149.90 and a low of Rs 987.05, with the dates stated as 11 June, 2025 (high) and 02 April, 2026 (low). The text also notes the stock is 45.73% below its 52-week high and 18.21% above its 52-week low. The company’s market capitalisation was stated at Rs 12,206.62 crore.

Jefferies view: Hold maintained despite approval

Jefferies has maintained a ‘Hold’ rating on Concord Biotech. The brokerage’s target price was cited at Rs 1,020. Jefferies noted that the company’s Q4FY26 performance fell short of expectations. The reasons flagged were delays in order execution and regulatory approvals. The note also points to the order book as a near-term visibility indicator. Alongside that, Jefferies mentioned potential improvement in EBITDA margin, while also flagging a risk factor related to possible delays in tender allocation.

Financial and operating metrics cited in the update

The information provided includes specific financial figures that investors may keep in context alongside the approval. Revenue was stated to have fallen 24.1% to Rs 326.1 crore, and EBITDA margins were stated to have declined from 44.3% to 36.4%. Separately, the company’s revenues for Q2FY26 were stated at Rs 247 crore, and H1FY26 revenues at Rs 451 crore. EBITDA was cited at Rs 88 crore for Q2FY26 and Rs 150 crore for H1FY26, compared to Rs 218 crore (as provided in the text). These data points show the market is balancing a regulatory positive with recently reported variability in execution and profitability.

Board decisions: audited results and dividend

The provided text references an outcome of a board meeting held on Friday, May 29, 2026. The board considered and approved the audited financial results and statements for the financial year ended March 31, 2026. It also approved the Directors’ Report for the same year. A dividend of Re 7.55 per equity share was mentioned. The board also approved the appointment of internal and cost auditors. Additionally, it noted the appointment of Mrs. Ekta Gupta as an Independent Director (Additional).

Broader US strategy signals mentioned alongside approvals

Beyond the Mycophenolate approval, the provided information also references other regulatory progress. It notes the company received USFDA approval to market Teriflunomide Tablets, described as an addition to the portfolio. It also states that Stellon Biotech Inc. was incorporated to drive the marketing, distribution, and commercialization of Concord Biotech’s products in the US market. Together, these points indicate the company has been pairing approvals with steps related to go-to-market readiness. However, the brokerage commentary included in the text suggests execution timing remains a key variable.

Key facts at a glance

What investors may watch next

The immediate focus is likely to remain on how quickly the approved product translates into commercial execution in the US market. Investors may also track updates on order execution and regulatory timelines, given Jefferies cited these as reasons behind the Q4FY26 miss versus expectations. The company’s stated order book visibility for the first half of FY2026-27 will remain a key data point in market discussions. The board-approved dividend and audited FY26 results provide additional checkpoints for shareholders. Any further announcements linked to US commercialization through Stellon Biotech Inc. could also shape near-term attention.